Arrowhead Pharmaceuticals, Inc.
NASDAQArrowhead Pharmaceuticals has clawed back some ground after a brutal month, with the stock up 4.5% on Tuesday to $71.86 — a small but meaningful recovery from the 17% selloff documented last week, and the first sign that sellers may be losing momentum. The stabilisation in price is mirrored in short positioning. Short interest has effectively flatlined over the past week, edging up…
ARWR short interest surged 20.3% in one day to 7.0% of float, driven by a sharp spike in borrowed shares despite ample availability at 2,283%.
Arrowhead Pharmaceuticals has clawed back some ground after a brutal month, with the stock up 4.5% on Tuesday to $71.86 — a small but meaningful recovery from the 17% selloff documented last week, and the first sign…
Arrowhead Pharmaceuticals enters the week in an uncomfortable position — the stock has shed 17% in five sessions while short sellers quietly rebuild positions, even as a freshly initiated Citigroup Buy rating anchors…
Snapshot as of 10 Oct 2026
Arrowhead Pharmaceuticals heads into its August 7 earnings report with the most bullish analyst consensus momentum it has seen in months, even as short sellers quietly pare back positions. The analyst signal is the…
Arrowhead Pharmaceuticals heads into its August 4 earnings report with options traders abruptly more defensive — even as short sellers have been quietly retreating for weeks. The sharpest signal right now is in the…
Arrowhead Pharmaceuticals heads into the final days of Q2 with shorts unwinding rapidly, options skewing heavily toward calls, and the Street largely constructive ahead of an August earnings catalyst. The short side of…
Arrowhead Pharmaceuticals enters the back half of June with short sellers quietly retreating and the Street turning more constructive — a combination that has helped the stock add 4.4% on the week to $76.55, even as it…
Arrowhead Pharmaceuticals enters late May with its strongest Street reception in months — yet options traders are quietly buying more protection than usual, creating a rare split between institutional conviction and…
Arrowhead Pharmaceuticals heads into mid-May with a striking divergence: the Street is growing more constructive, yet short sellers are rebuilding positions at their fastest weekly pace in over a month. Short interest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARWR — free to start on ORTEX.
Sign up for free →Open ARWR on ORTEX